ONLINE APPENDIX

Role of the Sponsor

The sponsors had no role in the design and conduct of the study, collection, management, analysis, and interpretation of the data, nor in preparation, review, and approval of the manuscript.

Additional contributions

PROSPER

The PROSPER study group: Executive Committee—(Glasgow) J Shepherd (Chairman and Principal Investigator), SM Cobbe, I Ford, A Gaw, PW Macfarlane, CJ Packard, DJ Stott; (Leiden) GJ Blauw (Principal Investigator), ELEM Bollen, AM Kamper, RGJ Westendorp; (Cork) MB Murphy (Principal Investigator), BM Buckley, M Hyland, IJ Perry. Endpoint Committee—SM Cobbe (Chairman), JW Jukema, PW Macfarlane, AE Meinders, DJ Stott, BJ Sweeney, C Twomey. Data And Safety Monitoring Committee—WV Brown (Chairman), H-C Diener, J Feely, I Ford (Non-voting), T Pearson, S Pocock, PA van Zwieten.

The Rotterdam Study

Management of the Rotterdam Study: the Rotterdam Study is directed by a Management Team comprising Jan Heeringa, MD, study coordinator, Eric Neeleman, head IT, Frank van Rooij, head data-management, and the scientific principal investigators Albert Hofman (PI Rotterdam Study, chairman), Monique Breteler (PI Neurological diseases), Cornelia van Duijn (PI Genetic studies), Gabriel Krestin (PI Radiology), Huibert Pols (PI Endocrinology), Bruno Stricker (PI Pharmacoepidemiology), Henning Tiemeier (PI Psychiatric diseases), Andre´ Uitterlinden (PI Genome wide analysis), Johannes Vingerling (PI ophthalmologic diseases) and Jacqueline Witteman (PI Cardiovascular diseases). The contribution of inhabitants, general practitioners and pharmacists of the Ommoord district to the Rotterdam Study is greatly acknowledged.